Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2019 | 237 | 0.77 | Why? |
| Polyesters | 1 | 2019 | 94 | 0.76 | Why? |
| Cholangitis | 1 | 2019 | 81 | 0.72 | Why? |
| Plastics | 1 | 2019 | 463 | 0.59 | Why? |
| Drug-Eluting Stents | 1 | 2019 | 562 | 0.49 | Why? |
| Pancreatitis | 1 | 2017 | 688 | 0.37 | Why? |
| Extravascular Lung Water | 2 | 2021 | 32 | 0.27 | Why? |
| Anti-Bacterial Agents | 3 | 2020 | 10083 | 0.25 | Why? |
| Meningitis, Pneumococcal | 1 | 2021 | 35 | 0.22 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2021 | 66 | 0.21 | Why? |
| Capillary Permeability | 2 | 2021 | 277 | 0.20 | Why? |
| Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2018 | 3 | 0.20 | Why? |
| Tuberculosis, Meningeal | 1 | 2021 | 100 | 0.20 | Why? |
| Pulmonary Edema | 2 | 2021 | 430 | 0.19 | Why? |
| Drug Liberation | 1 | 2019 | 141 | 0.19 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2021 | 170 | 0.19 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Bacterial Adhesion | 1 | 2018 | 69 | 0.18 | Why? |
| Sutures | 1 | 2018 | 57 | 0.18 | Why? |
| Fumarates | 1 | 2017 | 38 | 0.17 | Why? |
| Cardiac Output | 1 | 2017 | 183 | 0.16 | Why? |
| Renin | 1 | 2017 | 167 | 0.16 | Why? |
| Chlorhexidine | 1 | 2018 | 176 | 0.15 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2018 | 604 | 0.13 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 634 | 0.13 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.12 | Why? |
| Catheterization, Central Venous | 1 | 2017 | 458 | 0.12 | Why? |
| Surgical Wound Infection | 1 | 2018 | 501 | 0.12 | Why? |
| Antimicrobial Stewardship | 1 | 2020 | 931 | 0.12 | Why? |
| Pyridines | 1 | 2018 | 680 | 0.11 | Why? |
| Contrast Media | 1 | 2017 | 1011 | 0.11 | Why? |
| Anti-Infective Agents, Local | 1 | 2018 | 520 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.11 | Why? |
| Lymphocyte Activation | 1 | 2021 | 2742 | 0.11 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.11 | Why? |
| Monitoring, Physiologic | 2 | 2021 | 1956 | 0.10 | Why? |
| Microbial Sensitivity Tests | 1 | 2019 | 2886 | 0.10 | Why? |
| Thermodilution | 2 | 2021 | 62 | 0.10 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.10 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Stroke Volume | 1 | 2017 | 2153 | 0.08 | Why? |
| Pancreatitis, Chronic | 1 | 2007 | 37 | 0.08 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.08 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.08 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.07 | Why? |
| Amides | 1 | 2017 | 1864 | 0.07 | Why? |
| Germany | 4 | 2021 | 9196 | 0.07 | Why? |
| Antihypertensive Agents | 1 | 2017 | 1962 | 0.07 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.07 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Algorithms | 1 | 2021 | 7346 | 0.07 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.06 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.06 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.06 | Why? |
| Mesylates | 1 | 2021 | 33 | 0.06 | Why? |
| Spirochaetales Infections | 1 | 2021 | 10 | 0.06 | Why? |
| Practice Patterns, Physicians' | 1 | 2020 | 4927 | 0.06 | Why? |
| Sulbactam | 1 | 2020 | 37 | 0.06 | Why? |
| Renin-Angiotensin System | 1 | 2017 | 3661 | 0.06 | Why? |
| Ampicillin | 1 | 2020 | 73 | 0.05 | Why? |
| Brain Abscess | 1 | 2021 | 50 | 0.05 | Why? |
| Galactose | 1 | 2021 | 201 | 0.05 | Why? |
| Granzymes | 1 | 2021 | 197 | 0.05 | Why? |
| Female | 12 | 2021 | 380317 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Urea | 1 | 2021 | 228 | 0.05 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.05 | Why? |
| Mannans | 1 | 2021 | 218 | 0.05 | Why? |
| Male | 11 | 2021 | 367725 | 0.05 | Why? |
| Linezolid | 1 | 2020 | 160 | 0.05 | Why? |
| Stents | 1 | 2007 | 916 | 0.05 | Why? |
| Aged | 9 | 2021 | 215776 | 0.05 | Why? |
| Glucose Clamp Technique | 1 | 2018 | 39 | 0.05 | Why? |
| Esters | 1 | 2021 | 300 | 0.05 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 5277 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Imines | 1 | 2018 | 15 | 0.05 | Why? |
| Humans | 18 | 2021 | 930598 | 0.05 | Why? |
| HLA-DR Antigens | 1 | 2021 | 563 | 0.05 | Why? |
| Femoral Vein | 1 | 2017 | 43 | 0.04 | Why? |
| Emtricitabine | 1 | 2018 | 202 | 0.04 | Why? |
| Chemotherapy, Adjuvant | 1 | 2021 | 606 | 0.04 | Why? |
| Vancomycin | 1 | 2020 | 328 | 0.04 | Why? |
| Jugular Veins | 1 | 2017 | 52 | 0.04 | Why? |
| Adult | 8 | 2021 | 244371 | 0.04 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.04 | Why? |
| Streptococcal Infections | 1 | 2020 | 255 | 0.04 | Why? |
| Microscopy, Electron, Scanning | 1 | 2018 | 221 | 0.04 | Why? |
| Aspergillosis | 1 | 2020 | 264 | 0.04 | Why? |
| Middle Aged | 9 | 2021 | 270681 | 0.04 | Why? |
| Escherichia coli Infections | 1 | 2020 | 348 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.04 | Why? |
| Guanidines | 1 | 2021 | 499 | 0.04 | Why? |
| Injections, Intravenous | 1 | 2017 | 381 | 0.04 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.04 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.04 | Why? |
| Interleukin-17 | 1 | 2021 | 602 | 0.04 | Why? |
| Blood Component Transfusion | 1 | 2021 | 740 | 0.04 | Why? |
| Adenine | 1 | 2018 | 463 | 0.04 | Why? |
| Klebsiella Infections | 1 | 2020 | 466 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.04 | Why? |
| HIV Infections | 1 | 2021 | 11620 | 0.04 | Why? |
| Tenofovir | 1 | 2018 | 449 | 0.04 | Why? |
| Enterobacteriaceae Infections | 1 | 2020 | 529 | 0.03 | Why? |
| Systems Analysis | 1 | 2018 | 366 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2021 | 25144 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| T-Lymphocyte Subsets | 1 | 2021 | 1387 | 0.03 | Why? |
| History, 21st Century | 1 | 2020 | 1849 | 0.03 | Why? |
| Severity of Illness Index | 4 | 2021 | 48226 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.03 | Why? |
| Sepsis | 2 | 2021 | 3517 | 0.03 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 1439 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Staphylococcal Infections | 1 | 2020 | 1099 | 0.03 | Why? |
| Plasma | 1 | 2021 | 1809 | 0.03 | Why? |
| Shock, Septic | 1 | 2021 | 1313 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2021 | 2093 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2021 | 2483 | 0.03 | Why? |
| Antifungal Agents | 1 | 2020 | 1828 | 0.02 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.02 | Why? |
| Heart | 1 | 2017 | 1791 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.02 | Why? |
| Dilatation | 1 | 2007 | 181 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.02 | Why? |
| Tuberculosis | 1 | 2021 | 2895 | 0.02 | Why? |
| Pain Measurement | 1 | 2007 | 533 | 0.02 | Why? |
| Tertiary Care Centers | 1 | 2021 | 8248 | 0.02 | Why? |
| Pain, Postoperative | 1 | 2007 | 289 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.02 | Why? |
| Disease Progression | 1 | 2021 | 13580 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2021 | 8041 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Lung | 2 | 2021 | 31049 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.01 | Why? |
| Critical Illness | 1 | 2021 | 17281 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Recurrence | 1 | 2007 | 3675 | 0.01 | Why? |
| Endoscopy | 1 | 2007 | 1564 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| Pandemics | 1 | 2021 | 389249 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2021 | 243684 | 0.01 | Why? |
| Patient Selection | 1 | 2007 | 4560 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2007 | 17020 | 0.01 | Why? |
Schneider's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(172)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(139)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_